Evidence map›Paper›PMID 35249967›Full record

ReviewCurrent opinion in urology2022

Reimbursement of surgical procedures for benign prostatic hyperplasia: are we disincentivizing complex care?

Gopal Narang, Daniel Kellner, Amy Krambeck, Mitchell Humphreys

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current opinion in urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Early experience of "Urology annals
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Gopal NarangMayo Clinic Arizona Department of Urology, Phoenix, Arizona.
Daniel KellnerYale Department of Urology, Hartford, Connecticut.
Amy KrambeckNorthwestern Department of Urology, Chicago, Illinois, USA.
Mitchell HumphreysMayo Clinic Arizona Department of Urology, Phoenix, Arizona.
Mayo Clinic in Florida · USHartford Financial Services (United States)Northwestern Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo provide an overview of how surgical benign prostatic hyperplasia (BPH) procedures are compensated in the United States and the implications of the current reimbursement system on the care of patients. RECENT

findingsThe resource-based relative value care system is Medicare's current reimbursement model. There is strong evidence that the current system does not adequately account for complex care. Consequently, for BPH surgical procedures, treatment options best suited for complex patients are not adequately reimbursed which may have implications on healthcare delivery and outcomes. SUMMARY: Inadequate reimbursement for certain BPH procedures may disincentivize the care of complex patients. Procedures such a holmium laser enucleation of the prostate are well suited for complex patients but have a steep learning curve. The incentive to learn and offer such procedures to complex patients may be unfairly influenced by reimbursement levels, which in the end penalizes patients and the treatments available to them.

Indexed as

Lasers, Solid-StateLaser TherapyProstatic HyperplasiaTransurethral Resection of ProstateAgedHumansMaleMedicareTreatment OutcomeUnited States

Identifiers

PMID35249967
OpenAlexW4220886056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.